Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Cizzle Biotechnology Holdings Plc is a biotechnology company focused on the early detection of cancer. The primary purpose of the company is to develop and commercialize a blood test technology specifically designed for the early detection of a range of cancers, with an initial emphasis on lung cancer. This innovative approach leverages molecular diagnostic techniques to facilitate early intervention, which can improve patient outcomes and potentially save lives. Cizzle Biotechnology operates in the biomedical research sector, contributing significantly to advancements in cancer diagnostics and personalized medicine. The company plays a crucial role in the healthcare market, providing tools for improved disease management and treatment strategies. Through its technology, Cizzle Biotechnology not only spans the biomedical and healthcare industries but also impacts insurance, policy-making, and public health sectors by potentially reducing healthcare costs associated with late-stage cancer treatments.
£0.03
+£0.00 (+0.00%)
EOD Jul 3, 2026
ROIC dropped from -87.30% to -1408.51%, capital efficiency is deteriorating. Negative free cash flow of -£498K. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£691K
▲ +68.1% YoY
Op. Margin
—
ROIC
-1408.51%
▼ -1321.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-£498K
▼ -39.1% YoY
Op. Cash Flow (TTM)
-£496K
▼ -38.5% YoY
Net Debt
-£116K
Net Cash Position
Cash & Equiv.
£116K
Continue Research
Cizzle Biotechnology Holdings (CIZ.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cizzle Biotechnology Holdings scores 10/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Cizzle Biotechnology Holdings scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,408.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CIZ.XLON's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.